Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-05-14
2001-02-06
Low, Christopher S. F. (Department: 1653)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023100, C536S023500, C435S320100, C435S007100, C435S325000, C436S501000, C530S350000, C530S300000, C530S825000, C424S243100
Reexamination Certificate
active
06183990
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces “functional genomics”, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on “positional cloning”. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tacked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to rhotekin, in particular rhotekin polypeptides and rhotekin polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, cancer, cardiovascular disorders, brain disorders, developmental disorders, cytoskeletal-associated disorders and signal transduction related diseases, hereinafter referred to as “diseases of the invention”. In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with rhotekin imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate rhotekin activity or levels.
REFERENCES:
patent: 5691147 (1997-11-01), Draetta et al.
patent: WO 95/33819 (1995-02-01), None
Waterston RH. Direct Submission, Jun. 12, 1998, Accession #AC 005041, Genome Sequencing Center.
GenBank Accession No. U54638, Reid et al., Jul. 14, 1996.
GenBank Accession No. W72722, Hillier et al., Oct. 16, 1996.
GenBank Accession No. AA928859, National Cancer Institute, Cancer Genome Anatomy Project, Jul. 7, 1998.
Reid et al. “Rhotekin, a New Putative Target for Rho Bearing Homology to a Serine/Threonine Kinase, PKN, and Rhonophilin in the Rho-binding Domain”, vol. 271(23), pp. 13556-13560 (1996).
Calmels Thierry Paul Gerard
Duecker Klaus Norbert
Han William T.
King William T.
Low Christopher S. F.
Ratner & Prestia
Robinson Hope A.
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2590853